📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

🧪

Mock / simulation document

This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.

📄

About this document — a plain-language guide

What it is. The Module 3 (Quality / CMC) index and overview tying together the drug substance, drug product, and supporting quality sections.

Why it exists. Module 3 proves the drug can be made consistently, purely, and stably. This index orients a reviewer to the S (substance), P (product), and appendix/regional sections that follow.

How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.

Format & governing standard. ICH M4Q(R1) (CTD Quality) · Q6B · Q5C · Q3A/B · Q11

Module 3 — Quality (CMC) — GLPI-103

Field	Value
Document ID	M3
Version	1.0
Compound	GLPI-103 (GLP-1/APJ dual agonist peptide)
Standard	ICH M4Q(R1) (CTD Quality) · Q6B · Q5C · Q3A/B · Q11
Confidentiality	Confidential — portfolio use

[MOCK — deep-knowledge assumption] No CMC wet-lab data are generated by this project. This module presents a scientifically coherent, guideline-structured Quality narrative for a synthetic peptide with two drug products (IV solution, oral tablet). All specifications/values are illustrative.

Change History

Version	Date	Author	Summary
1.0	2026-06-29	CMC / Quality	Initial version (knowledge-based mock)

3.2.S Drug Substance (GLPI-103)

S.1 General Information

Nomenclature: GLPI-103 (development code); a synthetic peptide dual agonist of the GLP-1 and Apelin (APJ) receptors.
Structure: linear/cyclized peptide with sequence and modifications (e.g., fatty-acid acylation for half-life extension, non-natural residues for protease resistance). Defined primary sequence; disulfide/cyclization as applicable.
Properties: amorphous/lyophilized solid; water-soluble; characteristic isoelectric point; molecular weight in the peptide range. [MOCK]

S.2 Manufacture

Manufacturer: named GMP site(s).
Process (Q11): solid-phase peptide synthesis (SPPS) with fragment coupling, side-chain deprotection, cleavage, and acylation; purification by preparative RP-HPLC; lyophilization. In-process controls at coupling, cleavage, and purification.
Control of materials & critical steps: defined critical process parameters (coupling efficiency, purification gradient) and acceptance criteria; control strategy per QbD where applicable.

S.3 Characterisation

Primary structure (peptide mapping, MS, amino-acid analysis, sequencing), higher-order structure (CD, NMR as applicable), and impurity characterization (deletion/insertion sequences, oxidation, aggregation/dimers). Biological activity by GLP-1R and APJ potency assays.

S.4 Control of Drug Substance

Attribute	Method	Acceptance (illustrative)
Identity	RP-HPLC retention + MS	Conforms
Assay (content)	RP-HPLC	95.0–105.0%
Related substances	RP-HPLC	Any single ≤0.5%; total ≤2.0%
Aggregates	SEC	≤1.0%
Counterion / water	IC / KF	Within limits
Bacterial endotoxin	LAL	≤ limit (parenteral)
Bioburden	Compendial	≤ limit

Analytical procedures validated per Q2(R2). Batch analyses and specification justification provided.

S.5 Reference Standards

Qualified primary and working reference standards with characterization and requalification protocol.

S.6 Container Closure

Drug substance stored in qualified containers (e.g., HDPE/foil) protecting from moisture/light.

S.7 Stability (Q5C/Q1A)

Long-term (−20 °C) and accelerated stability support the retest period; stability-indicating methods (RP-HPLC, SEC) demonstrate control of degradation (oxidation, aggregation). [MOCK]

3.2.P Drug Product

Two products are developed: P-IV (solution for IV infusion, once-weekly) and P-Oral (immediate-release tablet with permeation enhancer, once-daily).

P.1 Description & Composition

P-IV: sterile aqueous solution; buffer, tonicity agent, stabilizer; pH controlled.
P-Oral: tablet containing GLPI-103, a permeation enhancer (e.g., SNAC-type) to enable oral peptide absorption, plus standard excipients (filler, disintegrant, lubricant).

P.2 Pharmaceutical Development

Formulation rationale: solubility/stability for IV; enhancer selection and gastro-protection for oral bioavailability (links to biopharmaceutics, M2.7.1).
Compatibility, robustness, and dissolution development; control of critical quality attributes (assay, impurities, dissolution).

P.3 Manufacture

P-IV: compounding, sterile filtration, aseptic fill–finish; process validation; sterility assurance.
P-Oral: blending, compression, (coating), packaging; process validation.

P.4 Control of Excipients

Compendial excipients; the permeation enhancer controlled to its own specification.

P.5 Control of Drug Product

Attribute	P-IV	P-Oral
Appearance	Clear solution	Tablet, defined
Identity / Assay	RP-HPLC, 95–105%	RP-HPLC, 95–105%
Related substances	RP-HPLC	RP-HPLC
Dissolution	n/a	Q ≥80% at defined time
Uniformity of dosage units	—	Conforms
Sterility / Endotoxin	Conforms / ≤ limit	n/a
pH / Particulates	Within limits	n/a

P.6 Reference Standards

As per 3.2.S.5.

P.7 Container Closure

P-IV: glass vial / stopper, qualified for sterility and compatibility.
P-Oral: blister/HDPE with desiccant as needed.

P.8 Stability (Q1A/Q5C)

ICH-condition studies (long-term/accelerated) support shelf life and storage statements; stability-indicating methods confirm control of degradation. [MOCK]

3.2.A Appendices

Facilities and equipment; adventitious-agents safety (peptide synthetic origin minimizes viral/TSE risk; any animal-derived raw materials controlled).

3.2.R Regional Information

Region-specific quality information for FDA/EMA/MFDS (e.g., executed batch records, method validation packages, comparability) provided per regional requirements.